• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Chim Acta . Evaluation of 32 rapid tests for detection of antibodies against SARS-CoV-2

tetano

Editor, Senior Moderator
Clin Chim Acta


. 2021 Apr 27;S0009-8981(21)00141-8.
doi: 10.1016/j.cca.2021.04.016. Online ahead of print.
Evaluation of 32 rapid tests for detection of antibodies against SARS-CoV-2


Mette C Toll?nes[SUP] 1 [/SUP], P?l A Jenum[SUP] 2 [/SUP], Helene Kierkegaard[SUP] 3 [/SUP], Eirik Abildsnes[SUP] 4 [/SUP], Roar Magne B?vre-Jensen[SUP] 5 [/SUP], Anne C Breivik[SUP] 2 [/SUP], Sverre Sandberg[SUP] 6 [/SUP]



Affiliations

Abstract

Aims: To evaluate the analytical performance of 32 rapid tests for detection of antibodies against coronavirus SARS-CoV-2.
Materials and methods: We used at total of 262 serum samples (197 pre-pandemic and 65 convalescent COVID-19), and three criteria to evaluate the rapid tests under standardized and optimal conditions: (i) Immunoglobulin G (IgG) specificity "good" if lower limit of the 95% confidence interval was ?97.0%, "acceptable" if point estimate was ?97.0%, otherwise "not acceptable". (ii) IgG sensitivity "good" if point estimate was ?90.0%, "acceptable" if ?85.0%, otherwise "not acceptable". (iii) User-friendliness "not acceptable" if complicated to perform or difficult to read result, otherwise "good". We also included partial evaluations of three automated immunoassay systems.
Results: Sensitivity and specificity varied considerably; IgG specificity between 90.9% (85.9-94.2) and 100% (97.7-100.0), and IgG sensitivity between 53.8% (41.9-65.4) and 98.5% (91.0-100.0). Combining our evaluation criteria, none of the 28 rapid tests that detected IgG had an overall performance considered "good", seven tests were considered "acceptable", while 21 tests were considered "not acceptable". Four tests detected only total antibodies and were not given an overall evaluation. IgG sensitivity and/or specificity of the automated immunoassays did not exceed that of many rapid tests.
Conclusion: When prevalence is low, the most important analytical property is a test's IgG specificity, which must be high to minimize false positive results. Out of 32 rapid tests, none had a performance classified as "good", but seven were classified as "acceptable".

Keywords: COVID-19 serological testing; COVID-19 testing; SARS-CoV-2; analytical performance; antibody detection; point-of-care; rapid tests; user-friendliness.
 
Back
Top Bottom